PHASE I/II STUDY OF OXALIPLATIN, 5-FLUOROURACIL AND DOCETAXEL FOR SOLID TUMORS

奥沙利铂、5-氟尿嘧啶和多西他赛治疗实体瘤的 I/II 期研究

• 批准号: 7604283
• 负责人: Mary Mulcahy
• 金额: $ 0.55万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604283
• 关键词: PHASE; II; STUDY; OXALIPLATIN; FLUOROURACIL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The subject is being asked to participate in this research study because he/she has cancer which is not curable by surgery or radiation therapy. In addition, his/her cancer has either grown while on chemotherapy or is likely to grow while on common chemotherapy treatments. This study involves treatment with the chemotherapy drugs: oxaliplatin, 5-fluorouracil, and docetaxel (Taxotere). These drugs have been approved by the Food and Drug Administration (FDA) for the treatment of a wide variety of cancers; however, the combination is considered experimental. The recommended dose and schedule has yet to be determined when using all three chemotherapy drugs together. The purpose of this research study is to evaluate the effects (good and bad) of the combination of oxaliplatin, 5-fluorouracil, and docetaxel. In addition, the study is to determine the highest dose of docetaxel that can be given safely with oxaliplatin and 5-fluorouracil.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 受试者被要求参与这项研究，因为他/她患有癌症，无法通过手术或放射治疗治愈。此外，他/她的癌症要么在接受化疗时生长，要么在接受普通化疗时生长。这项研究涉及化疗药物奥沙利铂、5-氟尿嘧啶和多西紫杉醇(泰索帝)的治疗。这些药物已经被食品和药物管理局(FDA)批准用于治疗各种癌症；然而，这种组合被认为是试验性的。当三种化疗药物一起使用时，建议的剂量和时间表尚未确定。 本研究的目的是评价奥沙利铂、5-氟尿嘧啶和多西紫杉醇联合应用的疗效(好的和坏的)。此外，这项研究还将确定与奥沙利铂和5-氟尿嘧啶一起安全使用的多西紫杉醇的最高剂量。